Chief Scientific Officer - Mark Cooper
- Chief Scientific Officer
Professor Mark Cooper
Deputy Director and Chief Scientific Officer
Domain Head: Diabetes
Baker IDI Heart and Diabetes Institute
Phone: +61 3 8532 1362
As Chief Scientific Officer, Mark plays a senior role in the strategic directions of the institute emphasizing the important links among the various research Divisions in both basic and clinical science using state of the art techniques to address the medical problems of diabetes and cardiovascular disease.
Diabetes is a serious public health issue and the dramatic rise of diabetes in the community is a major concern.
The complications of diabetes include kidney disease, eye disease and vascular disease.
Diabetes is a major factor in cardiovascular disease and the most common cause of kidney failure in the western world.
Mark has received many awards and is an eminent researcher in the field of diabetes and its complications.
work has profoundly improved our understanding of this disease and has been of direct benefit to millions of sufferers around the world.
distinguished body of research has led to new treatments for sufferers of diabetes that are today considered standard.
has played a key role in translating exciting discoveries in the laboratory to clinical care with seminal studies defining various treatment strategies to reduce the burden of diabetic complications.
This has included landmark studies demonstrating the benefit of currently widely used drugs such as ACE inhibitors and AII antagonists in diabetic kidney disease.
work on the combination of ACE inhibitors and AII antagonists for use in the treatment of diabetic kidney disease has seen this therapy become widespread and is reducing the risk of end-stage renal failure.
Mark's group derives funding from multiple national and international sources including the New York-based Juvenile Diabetes Research Foundation
as well as from the NHMRC.
is a past recipient of an NHMRC Australia Fellowship.